Back
ESC Professional Premium Access

Effects of dapagliflozin in heart failure with preserved ejection fraction and chronic obstructive pulmonary disease: an analysis of the DELIVER trial

Session: State-of-the art treatment of HFmrEF and HFpEF in 2023
Topic: Treatment
Speaker: Doctor J. Butt (Copenhagen, DK)
Event: ESC Congress 2023

Congress Presentation

About the speaker

Doctor Jawad Haider Butt

Rigshospitalet - Copenhagen University Hospital, Copenhagen (Denmark)
1 presentation
0 follower

3 more presentations in this session

State-of-the-art lecture on treatment of HFmrEF and HFpEF in 2023: insights from RCTs

Speaker: Professor L. Kober (Copenhagen, DK)

Access
Slides
Video
Thumbnail

Effect of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction treated with beta-blockers: the DELIVER trial

Speaker: Doctor A. Peikert (Graz, AT)

Access
Abstract
Slides
Video
Thumbnail

Effect of dapagliflozin in patients in Asia with heart failure with mildly reduced or preserved ejection fraction: insights from DELIVER

Speaker: Doctor X. Wang (Boston, US)

Access
Abstract
Slides
Video
Thumbnail

Access the full session

State-of-the art treatment of HFmrEF and HFpEF in 2023

Speakers: Doctor J. Butt, Professor L. Kober, Doctor A. Peikert, Doctor X. Wang
Access
Video
Thumbnail

About the event

Image

ESC Congress 2023

25 August - 28 August 2023

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb